Tumour-associated p53 missense mutants act as driver oncogenes affecting cancer progression, metastatic potential and drug resistance (gain-of-function) 1 . Mutant p53 protein stabilization is a prerequisite for gain-of-function manifestation; however, it does not represent an intrinsic property of p53 mutants, but rather requires secondary events 2 . Moreover, mutant p53 protein levels are often heterogeneous even within the same tumour, raising questions on the mechanisms that control local mutant p53 accumulation in some tumour cells but not in their neighbours 2, 3 . By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/ Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA-and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment. Our results provide evidence for an unpredicted layer of mutant p53 regulation that relies on metabolic and mechanical cues.
Mutation of the TP53 gene is the most frequent genetic lesion in human cancers 1 . Numerous studies have clearly established that missense p53 mutants are dependent on a transformed context for full activation of their malignant potential 4 . This includes oncogenic signalling, in response to which mutant p53 proteins are post-translationally modified 5 , and tumour-specific mechanisms of protein hyper-stabilization 6 that oppose the inherent instability of p53 mutants observed in normal tissues 2 . Remarkably, mutant p53 accumulation has been reported to be often spatially heterogeneous in individual tumours 3, 7 , suggesting that its protein stability may be influenced by local environmental cues.
Aiming to identify cellular processes and biochemical pathways responsible for mutant p53 stabilization in cancer cells, we performed a high-content screening of FDA-approved drugs ( Supplementary Fig. 1A ) 8, 9 in MDA-MB-231 breast cancer cells, in which we monitored the variations of mutant p53 levels after drug administration (Supplementary Table 1 ). On filtering the results by reproducibility, toxicity, dose dependence and manual inspection of images, the best hits associated with decreased levels of mutant p53 were the cardiac glycoside ouabain, the antipsychotics spiperone and thioridazine, the antiparasitic agent ivermectin, and two entire classes of drugs, namely adrenergic agonists (for example, salmeterol) and mevalonate pathway inhibitors (statins) (Fig. 1a-c , Supplementary Figs . 1B,C and 5B and Supplementary Table 2 ). None of the compounds identified by our screening was able to reduce p53 messenger RNA levels, thus suggesting a post-transcriptional mechanism of action (Supplementary Fig. 2A ).
Confirming the reliability of our approach, adrenergic agonists (for example, isoprenaline) and ouabain have already been identified as p53-destabilizing agents 10, 11 . Thus, for further analysis, we focused on statins, a class of drugs clinically used to lower cholesterol plasma levels in patients with cardiovascular disease. Statins act by inhibiting HMG-CoA reductase (HMGCR), which catalyses mevalonic acid (MVA) synthesis (the first rate-limiting step of the metabolic pathway leading to cholesterol biosynthesis, namely the mevalonate pathway) 12 . Cerivastatin and simvastatin behaved similarly in reducing mutant p53 levels ( Fig. 1c and Supplementary  Figs. 2B and 5B) and cerivastatin induced mutant p53 cytoplasmic localization ( Supplementary Fig. 1D ). The decrease in the level of mutant p53 following administration of cerivastatin was timedependent and maximal after 48 h ( Fig. 1d and Supplementary  Fig. 5B ). Cerivastatin also reduced the levels of exogenously expressed mutant p53 R280K in MDA-MB-231 cells ( Fig. 1e and Supplementary Fig. 5B ).
To assess whether the mevalonate pathway is a general regulator of mutant p53 levels, we analysed the effects of cerivastatin on a panel of human tumour cell lines harbouring different p53 mutants or wild-type p53. As shown in Fig. 1f , the treatment caused a substantial reduction of mutant p53 protein levels in all of the tested cell lines (Fig. 1f and Supplementary Fig. 2C ), while wild-type p53 levels were unaffected ( Fig. 1f and Supplementary Figs. 1I and 5B). Consistently, statin treatment reduced the proliferation of cells expressing missense mutant p53, with no effect on cells expressing wild-type p53 or null for p53 (Fig. 1g) . Cerivastatin also induced mild cell death in MDA-MB-231 cells; however, inhibition of apoptosis by Z-VAD treatment did not prevent mutant p53 reduction, suggesting that mutant p53 levels were not altered as a consequence of cell death ( Supplementary Fig. 1E ). In line with this result, induction of apoptosis in MDA-MB-231 cells by doxorubicin or 5-FU treatment did not reduce mutant p53 levels ( Supplementary  Fig. 1F ).
Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis
In MDA-MB-231 cells, cerivastatin shortened the half-life of both endogenous and overexpressed mutant p53 in a proteasomedependent manner ( Fig. 2a and Supplementary Fig. 1G,H) , and caused an increase of mutant p53 polyubiquitylated forms (Fig. 2b) . On the basis of this and other evidence 2, 13 , we hypothesized that statins could reactivate the ubiquitin-dependent degradation of mutant p53 in cancer cells. Indeed, administration of the MDM2 inhibitor nutlin, as well as specific knockdown of MDM2 caused a significant rescue of mutant p53 stability in cerivastatin-treated MDA-MB-231 cells (Fig. 2a,c,d and Supplementary Figs. 1J and 5B), thus suggesting that statin treatment affects mutant p53 levels via the MDM2 ubiquitin ligase. Of note, neither treatment was able to completely rescue mutant p53 levels, implying the existence of additional mechanisms mediating mutant p53 inhibition by statins.
In cancer cells, mutant p53 proteins are engaged in stable complexes with the Hsp90 chaperone, which is often upregulated during transformation 14 . This interaction results in a marked reduction of mutant p53 ubiquitylation by the E3 ligase MDM2 (Fig. 2e ) 15, 16 . As shown in Fig. 2f , cerivastatin caused the dissociation of Hsp90 from mutant p53, while its binding to MDM2 was unaffected ( Supplementary Fig. 5B ). These data suggest that inhibition of the mevalonate pathway in cancer cells restores the inherent instability of mutant p53 by functionally disrupting the molecular mechanism protecting mutant p53 from inhibition by MDM2.
It has been shown that HDAC6-mediated Hsp90 deacetylation fosters mutant p53 stabilization 17, 18 . Of note, statins have been found to inhibit HDAC enzymatic activity in tumour cells 19, 20 . We thus hypothesized that HMGCR inhibition could reduce HDAC6 activity, leading to Hsp90 acetylation (inactivation) and mutant p53 destabilization. As shown in Supplementary Fig. 2D , cerivastatin treatment indeed inhibited HDAC6, leading to increased tubulin acetylation. Of note, cerivastatin treatment induced an increase of Hsp90 acetylation, which was comparable to that induced by sulforaphane (a HDAC6 inhibitor 17, 21 ) ( Supplementary Fig. 2E ). These results suggest that HMGCR inhibition reduces Hsp90 activity as a consequence of HDAC6 inhibition.
All enzymes belonging to the mevalonate pathway are under direct transcriptional control of sterol regulatory element-binding -100 -100 Student's t-test was used. All experiments were repeated three times, apart from that in a, which was performed twice. Source data for g are available in Supplementary Table 6 . Unprocessed original scans of blots are shown in Supplementary Fig. 6 .
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NATuRe Cell BiOlOgy protein (SREBP) transcription factors (Fig. 3a ) 22 . Knockdown of either SREBP1 or SREBP2 in MDA-MB-231 cells coincided with a significant decrease of mutant p53 protein levels ( Fig. 3b and Supplementary Fig. 5B ). Conversely, activation of endogenous SREBP1/2 by culturing cells in lipoprotein-depleted serum increased mutant p53 protein levels, and this effect was nullified by inhibiting the mevalonate pathway with statins ( Fig. 3c and Supplementary  Fig. 5B ). Remarkably, mutant p53 protein levels were rescued in cerivastatin-treated MDA-MB-231 cells by addition of MVA, consistent with mutant p53 levels being dependent on intracellular mevalonate levels ( Fig. 3d and Supplementary Fig. 5B ). These results demonstrate that activation of the SREBP-mevalonate pathway promotes the accumulation of mutant p53 protein in cancer cells.
In addition to being responsible for de novo biosynthesis of cholesterol, the mevalonate pathway is essential for the production of other key metabolites, such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate (Fig. 3a ) 23 . Interestingly, only the geranylgeranyl transferase 1 (GGTase1) inhibitor GGTI-298 and the farnesyl di-phosphate synthase inhibitor zoledronic acid (ZA) were able to phenocopy the effect of statins on mutant p53, whereas the inhibition of squalene synthase by YM-53601 and farnesyl transferase by FTI-277 were ineffective (Fig. 3e,f and Supplementary  Fig. 5B ). GGTI-298 treatment induced MDM2-dependent mutant p53 ubiquitylation ( Supplementary Fig. 2F ), due to inhibition of HDAC6, consequent increase of Hsp90 acetylation and dissociation of mutant p53 ( Fig. 3i and Supplementary Figs. 2D,E and 5B). The effects of GGTI-298 were partially rescued by either proteasome or MDM2 inhibition ( Supplementary Fig. 2G,H) . Geranylgeranyl pyrophosphate (GGPP) addition to statin-treated cells, instead, rescued both mutant p53 levels ( Fig. 3g and Supplementary Fig. 5B ) and activation (as measured by the expression of the 'ten genes' signature 5 , Supplementary Fig. 4A ) as well as cell proliferation ( Fig. 3h and Supplementary Fig. 4B ). These data indicate that protein geranylgeranylation is required for mutant p53 accumulation in cancer cells.
The main biological role of geranylgeranylation is anchoring proteins to cellular membranes 24 . Rho-GTPases represent major GGTase1 targets and statins have been found to inhibit the enzymatic activity of RhoA 8 . Interestingly, RhoA has recently been identified as a key mediator of the anti-tumour activity of statins, and a crucial target of mutant p53 in controlling cellular metabolism 8, 12, 25, 26 . Therefore, we asked whether RhoA might control mutant p53 levels downstream of MVA. Strikingly, inhibition of RhoA, by means of either short interfering RNA (siRNA) or treatment with its specific inhibitor C3 toxin, was able to reduce mutant p53 protein levels in different cancer cell lines (Fig. 4a,b and Supplementary  Figs . 2I,J and 5B). As expected, treatment of MDA-MB-231 cells with C3 shortened mutant p53 half-life ( Supplementary Fig. 2K ). Conversely, overexpression of a constitutively active form of RhoA and 5B) that were completely prevented by treatment with GGTase1 inhibitor ( Fig. 4c and Supplementary Fig. 5B ). Importantly, in cells expressing a statin-sensitive but GGTI-insensitive GFP-RhoA mutant (RhoA-G14V-F) 8, 27 , GGTase1 inhibition was less efficient in reducing mutant p53 levels and cell proliferation ( Fig. 4d and Supplementary Figs . 2M,N and 5B), thus proving that RhoA prenylation is required for mutant p53 accumulation. Finally, knockdown of RhoA expression reduced the binding of Hsp90 to mutant p53 ( Fig. 4f and Supplementary Fig. 5B ). Together, these results implicate the activation of RhoA in the regulation of mutant p53 protein levels.
RhoA is a master regulator of actin cytoskeleton rearrangements and its activity is fundamental for transducing mechanical inputs generated by the extracellular/intracellular environment 28 . Thus, we asked whether acto-myosin dynamics control mutant p53 levels downstream of mevalonate-RhoA signalling. First, we analysed the impact of the mevalonate pathway on actomyosin dynamics by treating cells with cerivastatin, and monitoring phalloidin and pMLC2(Ser19) staining, as readouts of F-actin polymerization and of RhoA-dependent contractile myosin, respectively. Strikingly, inhibition of the mevalonate pathway by statin or ZA caused a dramatic reduction in both F-actin polymerization and MLC2 phosphorylation, as also observed following latrunculin A treatment, suggesting that the mevalonate pathway is functionally required for RhoA-dependent mechanotransduction in vitro ( Fig. 5a and Supplementary Fig. 3A ,B). A direct demonstration of actin cytoskeleton de-structuring has been provided by the significant reduction in cell stiffness observed in ZA-and statin-treated cells (P < 0.001), and measured by means of atomic force microscopy (AFM) (Fig. 5b ). Similar effects have been observed in blebbistatin-or Rho-kinase (ROCK)-inhibitor treated cells (Fig. 5b) . Interestingly, geranylgeranyl pyrophosphate was able to reverse statin effects, increasing cellular stiffness to levels comparable to those observed in untreated cells (Fig. 5b) . To test whether disruption of actin 
NATuRe Cell BiOlOgy cytoskeleton affects mutant p53 levels, we administrated latrunculin A to MDA-MB-231 cells and stained cells for F-actin and p53. As shown in Fig. 5c , latrunculin A elicited attenuation of F-actin stress fibres and concomitant reduction of mutant p53 levels ( Fig. 5c and Supplementary Fig. 3E ). Similarly, actin contractility inhibition or Rho-Kinase inhibition reduced mutant p53 levels ( Fig. 5b and Supplementary Fig. 3C,D) . Of note, in statin-treated cells, the effect of mevalonate addition on mutant p53 levels was nullified by latrunculin A (Supplementary Fig. 3F ). These results suggest that RhoA-dependent acto-myosin dynamics affect mutant p53 levels in tumour cells.
We then evaluated the role of the mevalonate pathway in tumour mechanosignalling and the effects of this on mutant p53 accumulation in vivo. To this end, we used archival tumour tissues from nude mice orthotopically injected with MDA-MB-231 cells and treated with ZA. In these mice, ZA caused a significant reduction of tumour growth 8 . Tumour tissues were then analysed for markers of mechanosignalling and for mutant p53 levels. Of note, tumour samples from mice receiving ZA showed a robust reduction of mechanosignalling, as indicated by decreased phosphorylation of focal adhesion kinase (pFAK residue Tyr397) and of myosin light chain 2 (pMLC2 residue Ser19) (Fig. 5d) . Accordingly, ZA treatment significantly decreased mutant p53 levels (Fig. 5d) . Interestingly, AFM analysis of tumour tissues showed that ZA treatment also reduced the stiffness of the cancer cells and of the extracellular matrix within the tumour (Supplementary Fig. 3O ).
Aberrant tissue tensional homeostasis is a feature of several epithelial cancers 29 . In this context, RhoA becomes activated by tissue rigidity and is part of an integrated mechanoregulatory circuit linking extracellular matrix stiffness to cytoskeletal tension ( Supplementary Fig. 3G,H) 
29
. On the basis of these premises, we postulated that matrix stiffness might act as an environmental input promoting mutant p53 stabilization through mevalonateRhoA-mediated mechanosignalling. To verify this hypothesis, we employed a pre-neoplastic experimental system, mammary epithelial cells (MECs) isolated from 8-week-old p53 R172H/R172H knock-in mice. These cells were grown either on a soft fibronectin-coated hydrogel matching the compliance of normal mammary tissue (Young's modulus: 0.5 kPa) 29, 30 , or on a stiff fibronectin-coated hydrogel (Young's modulus: 50 kPa) ( Fig. 5e and Supplementary  Fig. 5B ). As expected, mutant p53 levels were almost undetectable in MECs plated on soft matrix, confirming that the protein is intrinsically unstable in non-transformed tissues (Fig. 5e) . Strikingly, however, mutant p53 accumulated at high levels when MECs were grown on a hyperstiff matrix, and inhibition of the mevalonate pathway by cerivastatin treatment prevented its accumulation (Fig. 5e ). Cancer cells grown on soft fibronectin-coated hydrogels also showed significantly lower mutant p53 protein levels and activation (measured by the 'ten genes' signature 5 ) ( Fig. 5f and Supplementary Fig. 3H,N) as well as reduced levels of the enzymes involved in protein geranylgeranylation (namely Ggps1 and GGTase-1) and RhoA activation ( Supplementary Fig. 3G,I ). Of note, inhibition of actin polymerization by latrunculin A and treatment with cerivastatin both reduced mutant p53 levels and activation with similar efficiency (Fig. 5f and Supplementary Fig. 5B ). Overexpression of activated RhoA (RhoA-G14V) in cells grown on soft matrix efficiently promoted stabilization of mutant p53 to levels observed in cells grown on plastic (Fig. 5g and Supplementary  Fig. 5B ). Notably, in cells grown on soft hydrogels, Hsp90 is acetylated due to HDAC6 inhibition, and consequently is less efficient in binding mutant p53 (Fig. 5h and Supplementary Figs. 2D,E and 5B). Finally, while growing cells on stiff matrix induced mutant p53 accumulation, the concomitant inhibition of HDAC6 prevented this effect (Fig. 5i and Supplementary Figs. 3J,K and 5B), thus demonstrating the functional requirement of HDAC6 for mutant p53 stabilization downstream of RhoA/mechanical cues. These results demonstrate that mutant p53 proteins are not intrinsically stable in tumour cells, rather their accumulation is strongly influenced by the mevalonate-RhoA axis and by mechanical cues such as the stiffness of the extracellular environment.
We then decided to verify whether increased mechanosignalling correlates with mutant p53 activation in human tumours. To this end, we performed and validated gene expression analysis on MDA-MB-231 cells grown on either a soft or stiff surface and generated a 'stiffness' signature, composed of genes induced in stiff as compared with soft matrix (Supplementary Fig. 4D and Supplementary -100 -100 -100 -100 -100 -100
-100
-70 
Letters
NATuRe Cell BiOlOgy Table 5 ). Next, we interrogated a data set of 117 missense mutant p53 human breast cancers and classified tumours as having high or low expression of this 'stiffness' signature. When we monitored the activation of mutant p53 in these tumours, by analysing expression of a published 'mutant p53 signature' 31 , we found that tumours classified as 'highly stiff ' were also characterized by strong activation of mutant p53 (Fig. 5j) . As a positive control, the YAP/TAZ signature 32 was also upregulated in the same specimens [32] [33] [34] , indicating a parallel between activation of a widely validated mechanosensitive cascade and of mutant p53 in primary human tumours ( Fig. 5k and Supplementary Fig. 5A ). These observations confirm that mutant p53 is more active in cells with activated mechanosignalling. Of note, YAP/TAZ were not involved in mutant p53 stabilization, as YAP or YAP/TAZ knockdown had no effects on mutant p53 levels in stiff matrix or in cells overexpressing the active form of RhoA ( Supplementary Fig. 3L,M) . , classified according to the 'stiffness' signature (as in j). In k and j, data are shown as individual samples (n = 117 independent breast cancer patients, dots, obtained from the Molecular Taxonomy of Breast Cancer International Consortium, METABRIC) and the mean ± s.e.m. (standard error of the mean; back lines). ****P < 0.0001 in a two-tailed unpaired t-test. The experiments in a,e-i were repeated three independent times with similar results. The experiment in d was performed once. Unprocessed original scans of blots are shown in Supplementary Fig. 6 .
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In cancer cells, the mevalonate pathway can be activated by a direct mutant p53-SREBP interaction, which sustains SREBP transcriptional activity 35 . Combined with our finding that SREBP activation affects mutant p53 levels, this evidence supports the concept that in cancer cells mutant p53 can give rise to a positive feedback loop in which, by forcing mevalonate pathway activation and GGPP biosynthesis, mutant p53 can sustain its own stabilization. RhoA geranylgeranylation turns out to be an essential process in these events. This interplay could possibly require other proteins, such as HDAC6 17, 36, 37 . The Rho pathway may work in concert with other, possibly redundant or tumour-specific mechanisms to stabilize mutant p53. For example, activation of the Hsp40/DNAJ chaperone by the mevalonate pathway has recently been found to control mutant p53 stability 38 through the ubiquitin ligase chromatin immunoprecipitation. Although the involvement of cell mechanics was not investigated in that study, our work nonetheless defines a different pathway, involving Hsp90 and MDM2.
More importantly, we demonstrate that pharmacologic inhibition of the mevalonate-RhoA axis (for example, by statins, ZA or GGTI) can interfere with the transduction of mechanical inputs in vitro and in vivo and thereby prevent the stabilization of mutant p53 and of other oncogenes such as YAP/TAZ 8 , ultimately restraining diverse malignant cancer phenotypes.
Mutant p53 accumulation is often spatially heterogeneous within primary tumours, with mutant-p53-overexpressing tumour foci associated with fibrous stroma 3 . Our work shows that the extracellular microenvironment controls mutant p53 stabilization and activation. On this basis, we speculate that the heterogeneity of mutant p53 expression observed within individual tumours might be explained by different mechanical niches existing within the diseased tissues 30 . The presence of fibrotic 'stiff ' lesions, along with influencing treatment efficacy 39 , is associated with poor prognosis 40 , enhanced growth and survival signalling, and with invasive and pro-metastatic features 29 . Our results imply that conditions that increase ECM stiffening (fibrosis) and cell contractility in mutant p53 tumours could induce stabilization of mutant p53 and activation of its oncogenic properties, ultimately facilitating malignant progression.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-017-0009-8. MDA-MB-231, MDA-MB-468, BT-549, SKBR-3, U2OS, U118MG and T47D cells were cultured in DMEM (LONZA) supplemented with 10% fetal bovine serum (FBS) and with 1% antibiotics (penicillin 100 U ml -1 and streptomycin 10 μ g ml -1 ). SUM149 cells were cultured in DMEM/F12 (LONZA) (1:1) supplemented with 10% FBS and with 1% antibiotics. Hs-578-T were cultured in DMEM (Thermo Fisher) supplemented with 10% FBS, glutamine and antibiotics and 10 μ g ml -1 insulin (Sigma). Mahlavu cells were cultured in EMEM (Sigma) supplemented with 10% FBS, with 1% antibiotics (penicillin 100 U ml -1 and streptomycin 10 μ g ml -1 ), 1% MEM NEAA (minimum essential medium nonessential amino acids) and 1% Glutamax. H1299 cells were cultured in RPMI 1640 medium with 10% FBS and 1% antibiotics. MCF7 cells were cultured in EMEM (Sigma) supplemented with 10% FBS, with 1% antibiotics (penicillin 100 U ml -1 and streptomycin 10 μ g ml -1 ) and 1% MEM NEAA. MDA-MB-231 cells, stably expressing GFP-RhoA-G14V and the mutant GFPRhoA-G14V-F, were maintained in DMEM (LONZA) supplemented with 10% FBS and with 1% antibiotics (penicillin 100 U ml -1 and streptomycin 10 μ g ml -1 ) and with addition of selection antibiotics.
MEFs infected with pLPC-RAS V12 were maintained as previously described 5 . Mammary epithelial cells were isolated from p53 R172H/R172H knock-in mice as previously described 9, 41 and seeded on top of 50 kPa or 0.5 kPa Easy Coat hydrogels (Cell Guidance Systems) and harvested after three days. Hydrogels for the experiments in Fig. 5 were as in ref. 33 .
Reagents and plasmids.
The library of FDA-approved drugs (Screen-Well FDA-Approved Drug Library, 640 chemical compounds dissolved at 10 mM in dimethylsulfoxide) was obtained from Enzo Life Sciences.
The following compounds were purchased from Sigma Aldrich: cerivastatin (SML0005), ouabain (O3125), spiperone (S7395), ivermectin (I888), salmeterol (S5068), simvastatin (S6196), GGTI-298 (G5169), geranylgeranyl pyrophosphate (G6025), zoledronic acid (SML0223), mevalonic acid (41288), cycloheximide (C7698 and C1988), blebbistatin (B0560) and Y-27632 dihydrochloride (Y0503). Latrunculin-A (sc-202691) was purchased from Santa Cruz Biotechnology. The following compounds were purchased from Cayman: YM-53601 (18113), FTI-277 (F9803), Nutlin-3 (10004372) and SAHA (10009929). MG132 (474790) was purchased from Calbiochem. Thioridazine hydrochloride (1306110) was purchased from Tocris. C3-RhoA inhibitor I (CT04) was purchased from Cytoskeleton. Lipoprotein-depleted serum (LDS) (880100-2) was purchased from Biocompare (DBA). Z-Vad FMK was from Enzo Life Science (ALX-260-020-M001). 5-fluorouracile (5FU) was from Teva. Doxorubicin hydrochloride was from Sigma (D1515). Picro Sirus Red Stain Kit (Connective Stain) (ab 150681) was purchased from Abcam.
pEGFP-RhoA-G14V was a gift from C. Schneider (Laboratorio Nazionale CIB, Italy). The retroviral constructs (pLPC) coding for GFP-RhoA-G14V (CLVL) and GFP-RhoA V14 -F (CVLS) were generated by PCR mutagenesis from pEGFPRhoA-G14V 8 . pcDNA3-p53R280K was previously described 5 .
High-content screening. For the screening experiments, MDA-MB-231 cells (3.0 × 10 3 per well) were seeded on black clear-bottom 384-well plates (PerkinElmer). Twenty-four hours later, the FDA-approved drugs were transferred robotically from library stock plates (0.1 mM and 1 mM in DMSO) to the plates containing the cells; controls were added to columns 1, 2, 23 and 24 of each plate. Cells were fixed at 48 h after plating (that is, 24 h after addition of drugs), and processed immediately for immunofluorescence. Briefly, cells were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.5% Triton X-100 in phosphatebuffered saline (PBS) solution for 10 min, followed by 30 min blocking in 3% FBS. Cells were then incubated with a mouse antibody against mutant p53 (DO-1, Santa Cruz Biotechnology) diluted in blocking solution for 1 h. Cells were further washed with PBS and incubated for 1 h with a secondary antibody conjugated to Alexa Fluor-594 (Life Technologies), and stained with Hoechst 33342 (Life Technologies).
Image acquisition was performed using an ImageXpress Micro automated high-content screening fluorescence microscope (Molecular Devices) at × 10 magnification; a total of 9 images were acquired per wavelength, well and replicate, corresponding to about 4,500 cells analysed per experimental condition and replicate. Image analysis to identify cells presenting mutant p53 signal was performed using the 'Multi-Wavelength Translocation' application module implemented in MetaXpress software (Molecular Devices).
Screening was performed in duplicate, at two drug concentrations (1 μ M and 10 μ M); the final concentration of DMSO in the culture medium was 1% (v/v) for all experimental conditions. The screening was performed at the ICGEB HighThroughput Screening Facility (http://www.icgeb.org/high-throughput-screening.html).
Transfections. siRNA transfections were performed with Lipofectamine RNAi-MAX (Life Technologies) in antibiotic-free medium according to the manufacturer's instructions. Sequences of siRNAs are reported in Supplementary  Table 3 . Negative control siRNA was: AllStars negative control siRNA Qiagen 1027281. In Supplementary Fig. 3J , siHDAC6 was transfected two times to improve the efficiency of HDAC6 protein reduction.
DNA transfections were performed in MDA-MB 231 cell lines with Lipofectamine 2000 (Invitrogen) in antibiotic-free medium according to the manufacturer's instructions.
For retrovirus production, low-confluence HEK-293GP packaging cells were transfected with appropriate vectors by calcium phosphate, in combination with pMD2ENV coding for envelope proteins. After 48-72 h the virus-containing medium was filtered and added to target cells. Cells were selected with puromycin (0.5 μ g ml
−1
).
Quantitative real-time PCR. Cells were harvested in Qiazol lysis reagent (Qiagen) for total RNA extraction, and contaminant DNA was removed by DNase treatment. qRT-PCR analyses were carried out on retrotranscribed cDNAs with Quantitect reverse transcription kit (Qiagen) and analysed with Biorad CFX Manager software. Experiments were performed at least three times, with duplicate replicates. The quantification is based on the 2 −ΔΔCt method using the housekeeping gene histone 3 (H3) as a normalizer. PCR oligonucleotide sequences (F, forward; R, reverse) are reported in Supplementary Table 4 . To monitor activation of mutant p53, we measured mRNA expression of the 'ten genes' signature as previously described 5 .
Antibodies. The antibodies used for western blot and immunofluorescence were: anti-p53 (1:1,000; DO-1, Santa Cruz Biotechnology), anti-actin (1:5,000; C11, Sigma), anti-GAPDH (1:5,000; MAB374, Millipore), anti-SREBP1 (2A4) (1:500; sc13551, Santa Cruz Biotechnology), anti-SREBP2 (1:500; 557037, BD Bioscience), anti-SCD-1 (1:1,000; ab19862, Abcam), anti-vinculin (1:5,000; V4505, Sigma), anti-Hsp90 (1:1,000; sc13119, Santa Cruz Biotechnology), anti-HDAC6 (H-300) (1:1,000; sc-11420, Santa Cruz Biotechnology), acetylated-lysine antibody (1:1,000; 9441, Cell Signaling), anti-α -tubulin (1:5,000; T5168, Sigma), anti-acetylatedtubulin (1:1,000; T6793, Sigma), anti-GFP (1:1,000; home-made), anti-MDM2 (SMP14; SC-965, Santa Cruz Biotechnology), anti-MLC2 (1:1,000; 3672S, Cell Signaling), anti-pMLC2 (phospho Ser19) (1:1,000; 3675S, Cell Signaling), anti-FAK (C-20) (1:1,000; sc-558, Santa Cruz Biotechnology), anti-pFAK (phospho Tyr397) (1:1,000; ab81298, Abcam), anti-YAP (1:1,000; sc-15407, Santa Cruz Biotechnology), anti-TAZ (1:1,000; HPA007415, Sigma), anti-PSMA2 (1:1,000; sc-54671, Santa Cruz). Phalloidin was from Alexa Fluor (A12379) and anti-BrdU antibody (RPN202) was from GE Healthcare. Anti-cleaved PARP p85 fragment pAb was from Promega (G7341).
Immunofluorescence and western blot. Immunofluorescence staining was performed as previously described 8 . Briefly, cells were fixed in 4% paraformaldehyde for 10 min, washed in PBS, permeabilized with Triton 0.1% for 10 min and blocked in PBS FBS 3% for 30 min. Antigen recognition was performed by incubating primary antibody for 1 h at 37 °C and with goat anti-mouse Alexa Fluor 568 (Life Technologies) as a secondary antibody for 30 min at 37 °C. Nuclei were counterstained with Hoechst 33342 (Life Technologies).
Western blot analysis was performed as previously described 8 . The protein stability determination was performed as previously described 5 . Immunoblots were quantified using the ImageJ program, which measures the integrated density of bands corrected for background. Supplementary Fig 6 shows the average ratio density from at least three experiments ± s.d. Two-tailed Student's t-tests were performed to determine the statistical significance.
Co-immunoprecipitation. Co-immunoprecipitation experiments with endogenous proteins were performed using co-immunoprecipitation buffer (NaCl 120 mM, Tris-HCl pH 8 20 mM, EDTA 1 mM, NP40 0.5%) with protease inhibitors. Samples were cleared by centrifugation for 30 min at 13,000g at 4 °C and incubated for 2 h at 4 °C with anti-p53 antibody. After 1 h incubation with protein G-Sepharose (GE Healthcare), immunoprecipitates were washed three times in co-immunoprecipitation buffer, resuspended in sample buffer, and analysed by immunoblotting.
For ubiquitylation assays, cells were lysed in 2% SDS, 150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 1 mM phenylmethyl sulfonyl fluoride, 5 mM NaF, 1 mM Na 3 VO 4 , 0.5% (v/v) sodium deoxycholate with protease inhibitor cocktail (Sigma-Aldrich) and ubiquitin aldehyde 50 ng ml -1 . Cell lysates were diluted in immunoprecipitation buffer: 10 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM EDTA and 1% Triton. The anti-p53 antibody (DO-1; Santa Cruz) was covalently bound to protein G Sepharose (Amersham Biosciences, GE Healthcare) using 5 mg ml -1 dimethylpimelimidate (Pierce Biosciences, Thermo Fisher Scientific).
Isolation of GTP-loaded RhoA GTPase. The GTP-loaded form of RhoA was pulled down with GST-RHOTEKIN beads (Cytoskeleton), according to the manufacturer's instructions.
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Colony-formation assay. Five thousand cells were plated on 6 cm plates. The day after, the medium was supplemented with drugs as indicated in the figures. After 6 days, the cells were fixed with 4% paraformaldehyde (PFA) and stained for 30 min with Giemsa (Fluka) solution diluted 1:5 in water. The plates were washed with water, dried and scanned. Colony quantification was performed using ImageJ.
BrdU incorporation assay. Cells (3 × 10 4 ) were plated in 24-well plates. The day after, the medium was supplemented with DMSO or cerivastatin as indicated in the figures. At 48 h following the treatment, the DNA precursor bromodeoxyuridine (BrdU) (20 μ M) was added to the medium for 2-12 h before fixation. Briefly, the cells were fixed in 4% paraformaldehyde for 10 min, washed in PBS, permeabilized with Triton 0.1% for 10 min and washed three times with NaOH 50 mM solution and washed in PBS. Primary anti-BrdU antibody solution (1:2 dilution), to detect incorporated bromodeoxyuridine (BrdU), was used for 2 h at 37 °C and goat antimouse Alexa Fluor 568 (Life Technologies) was used as the secondary antibody for 1 h a 37 °C. Nuclei were counterstained with Hoechst 33342 (Life Technologies).
Mice and animal care. For in vivo studies, one million MDA-MB-231 cells were resuspended in 100 μ l of DMEM, and injected into the mammary fat of previously anaesthetized seven-week-old SCID female mice (1-3% isoflurane, Merial Italia SpA) as previously described 8 . At day 12 after cell injection, the mice were subjected to intravenous injection of zoledronic acid ((1-hydroxy-2-(1H-imidazoledronic acid-1-yl) ethylidene) (200 μ g kg -1 body weight), every 4 days until the end of the experiment (day 40). At day 40, the animals were euthanized and the primary tumours were extracted and directly frozen in liquid nitrogen. Tissues were lysed for immunoblot analysis or sectioned at 5 μ m, fixed and stained either with haematoxylin and eosin (H&E) for histological analysis or with Picro Sirius and haematoxylin to perform AFM analysis. Four tumours per group were used. The mice were used and housed in a specific pathogen-free (SPF) animal facility. Procedures involving animals and their care were performed in conformity with institutional guidelines (D.L. 116/92 and subsequent complementing circulars) and all experimental protocols were approved by the ethical Committee of the University of Padua (CEASA). The study is compliant with all relevant ethical regulations regarding animal research.
Microarray analysis for stiffness signature. For microarrays of genes regulated by matrix stiffness uptake, MDA-MB-231 cells were plated on soft fibronectincoated hydrogels, as compared with the same cells grown on fibronectin-coated rigid surfaces (plastic). For each experimental condition, four biological replicates were prepared and processed in parallel. Total RNA was extracted using TriPure (Roche). RNA quality and purity were assessed on the Agilent Bioanalyzer 2100 (Agilent Technologies); RNA concentration was determined using the NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies Inc.). Labelling and hybridization were performed according to Affymetrix One Cycle Target Labeling protocol on HG-U133 Plus 2.0 arrays (Affymetrix).
All data analyses were performed in R (version 3.2.4) using Bioconductor libraries (BioC 3.2) and R statistical packages. Probe level signals were converted to expression values using robust multi-array average procedure RMA 42 of Bioconductor affy package. Differentially expressed genes were identified using Significance Analysis of Microarray algorithm coded in the samr R package 43 . In SAM, we estimated the percentage of false-positive predictions (that is, false discovery rate, FDR) with 100 permutations. To identify genes associated with stiffness in cells of mammary origin (stiffness signature), we compared the expression levels of MDA-MB-231 cells grown on stiff (Young's modulus: 50 kPa) and soft hydrogels (Young's modulus: 0.5 kPa) and selected those probe sets with an FDR ≤ 1% and a fold change ≥ 1.5. This selection resulted in 220 probe sets induced in the stiff matrix (Supplementary Table 5 ).
Atomic force microscopy analysis. AFM was used to investigate cell mechanical properties. In particular, elastic assessment of stiffness was done taking advantage of the force spectroscopy capabilities of a Smena AFM (NT-MDT Co.) mounted on an inverted fluorescence microscope (Nikon Eclipse Ti-U). In brief, force spectroscopy measures the deflection of the AFM cantilever when it is pushed against a surface. Deflection data were subsequently converted into a force versus indentation curve based on cantilever spring constant and displacement knowledge 44 . Compliance of the material under the tip was determined in this work by fitting the data with a Hertzian model of surface indentation 45 . Cell stiffness was established by acquiring a single force spectroscopy curve in the central part of the cell, roughly corresponding to the nucleus position. The AFM tip was placed in the correct position above cells using an inverted microscope in bright field mode. Cells were measured in 1 × PBS buffer at room temperature. For each sample, 60 randomly chosen cells were measured and analysed. Tissue section stiffness was studied by evaluating the stiffness of the cells inside the tissue, marking their nuclei via haematoxylin staining, and ECM stiffness, visualizing it using the collagen-and amyloid-specific dye Picro Sirius Red Stain. AFM force curves were obtained on each sample (4 control, not treated, samples and 4 zoledronate-treated ones) randomly acquiring about 60 curves on blue, haematoxylin-positive, areas and about 60 curves on red, Picro Sirius Red-positive, areas (see Supplementary Fig. S3 ). A total number of 210 and 245 stiffness values were obtained for controls and treated cells, respectively; 240 and 239 curves were instead acquired for control and treated ECMs. During AFM characterization, sections were maintained immersed in 1 × PBS buffer at room temperature. The cantilever used was a tip-less probe characterized by a spring constant of about 0.03 nN nm -1 (HQ:CSC38 cantilevers from MikroMasch Co), at the end of which a 18-µ m-diameter silica bead (Thermo Fisher Scientific) was glued using UV curable glue (Norland Products Inc.). Force spectroscopy measurements were performed at constant speed (2.5 µ m s -1 ) and triggered to a maximum force applied to the sample of 5 nN. Elastic modulus values (E), in kPa, were determined by fitting obtained force-displacement curves with a Hertzian model for the tip used taking advantage of the NOVA (NT-MDT Co.) control and analysis software.
Statistics and data processing were performed using Igor Pro software (www.wavemetrics.com) and R statistical computing software (www.R-project.org). The significance of the differences in the data was established as equality of probability distributions via the Kolmogorov-Smirnov test.
Breast cancer gene expression data. We downloaded the METABRIC collection, comprising gene expression data and clinical annotations for 997 breast cancer samples, from the European Genome-Phenome Archive (EGA, http://www.ebi. ac.uk/ega/) under accession number EGAD00010000210 (2012). Original Illumina probe identifiers have been mapped to Entrez gene IDs using the Bioconductor illuminaHumanv3.db annotation package for Illumina HT-12 v3 arrays obtaining log 2 intensity values for a total of 19,761 genes. The TP53 status of 117 samples annotated as 'missense' mutant p53 was derived from ref. 46 .
Average signature expression and signature scores. Average signature expression of the mutant-p53 signature 31 and of the YAP/TAZ activity-signature 32 was calculated as the standardized average expression of all signature genes in sample subgroups. Samples were classified as 'stiffness high' or 'stiffness low' , summarizing the standardized expression levels of the ''stiffness' signature genes into a combined score with zero mean. The values shown in graphs are thus adimensional.
Statistics and reproducibility. The experiment for Fig. 1a was repeated two times. The experiment in Fig. 5d was completed once. All other experiments are representative of at least three independent repeats. Error bars represent mean ± s.d. from n = 3 biological replicates. P values were determined using twotailed Student's t-test as noted in the figure legends. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design
Sample size
Describe how sample size was determined.
No statistical method was used to determine sample size. The sample size was chosen to include at least three biological replicates.
Data exclusions
Describe any data exclusions. No data were excluded from the analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
Experiments were performed succesfully at least three times. All replication attempts were succesfull.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Animals were randomly put into cages and randomly assigned to experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigators were not blinded. The experiments were quantified and were relevant appropriate statistical tests performed.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
